Novo Nordisk CEO Mike Doustdar told the Financial Times that the pharmaceutical industry is only "scratching the surface" of the market, explaining why the company made a deal with Trump last year.

Investors are closely watching Novo Nordisk's stock, which has faced significant declines, as they await a crucial financial figure that could reverse the company's headwinds, with analysts questioning CEO Mike Doustdar's ability to boost earnings despite price cuts.